Shakeup at the top of FDA’s biosimilars division as Leah Christl departs for Amgen
The FDA on Friday announced that Leah Christl, director of the Therapeutic Biologics and Biosimilars Staff (TBBS) in the Office of New Drugs (OND), has …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
